Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52 results about "Disease irritable bowel" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders
InactiveUS20050137644A1Eliminates repeated surgeryOvercomes shortcomingElectrotherapyArtificial respirationDiseaseDisease irritable bowel
Method and system to provide therapy for obesity and gastrointestinal disorders such as FGIDs, gastroparesis, gastro-esophageal reflex disease (GERD), pancreatitis and ileus comprises vagal blocking and / or vagal stimulation. Vagal blocking may be in the afferent or efferent direction, and may be with or without stimulation pulses. Blocking may be provided by one of a number of different electrical blocking techniques. Electrical signals may be provided with an external stimulator in conjunction with an implanted stimulus-receiver, or an implanted stimulus-receiver comprising a high value capacitor for temporary power source. In one embodiment, the external stimulator may comprise an optional telemetry unit. The addition of the telemetry unit to the external stimulator provides the ability to remotely interrogate and change stimulation programs over a wide area network, as well as other networking capabilities,
Owner:NEURO & CARDIAC TECH
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ActiveUS20090048175A1Maintain good propertiesIncrease resistanceOrganic active ingredientsSenses disorderPhosphodiesteraseGastrointestinal cancer
The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
Owner:BAUSCH HEALTH IRELAND LTD
Method for treating cachexia with retinoid ligands
InactiveUS20070185055A1BiocideSilicon compound active ingredientsRetinoidObstructive Pulmonary Diseases
The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.
Owner:JIANG GUANG LIANG +2
Substituted piperazines as CB1 antagonists
InactiveUS20060241121A1Lower Level RequirementsOrganic active ingredientsNervous disorderDisease irritable bowelPharmaceutical medicine
Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
Owner:INTERVET INC
Method of treating gastrointestinal tract disease with purinergic receptor agonists
InactiveUS20020052336A1Increase secretionBiocideCarbohydrate active ingredientsDiseaseDisease irritable bowel
The invention provides a method of regulating water and mucin secretions and fluid transport in the gastrointestinal tract. The invention also provides a method for treating a gastrointestinal disease in which the mucosal barrier of the gastrointestinal system is impaired. The invention additionally provides a method for correcting disorders of fluid secretion or absorption in the gastrointestinal system. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor agonist, in an amount effective to regulate water and mucin secretions or to correct abnormal fluid transport in the gastrointestinal tract. The pharmaceutical composition used in this invention comprises a P2Y purinergic receptor agonist such as uridine 5'-diphosphate (UDP), uridine 5'-triphosphate (UTP), cytidine 5'-diphosphate (CDP), cytidine 5'-triphosphate (CTP), adenosine 5'-diphosphate (ADP), adenosine 5'-triphosphate (ATP), and their analogs; and dinucleotide polyphosphate compounds of general Formula (IV). Said compound is prepared in an oral form, an injectable form, or a suppository form, and administered to a patient.
Owner:INSPIRE PHARMA
Therapeutic agent for intestinal diseases and visceral pain
InactiveUS20050148632A1Receptor selectivity is unclearImprove securityBiocideAntipyreticDisease irritable bowelVisceral pain
The present invention relates to a therapeutic agent for irritable bowel syndrome of diarrhea type, ulcerative colitis, visceral pain or abdominal pain, which contains a compound of the following formula and which has 5-HT7 receptor antagonistic effect or an analogue thereof; and this therapeutic agent has an excellent therapeutic effect and a high safety:
Owner:AJINOMOTO CO INC
Method for treating irritable bowel syndrome and other functional gastrointestinal disorders
The invention relates to methods and compositions for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. The methods of the invention involve the administration, in a delayed-release capsule or tablet containing a mixture of peppermint oil and chlorophyll. Other ingredients that may also be effective treatments may be included. This method may be useful as a new and safer treatment for IBS and other functional gastrointestinal disorders. The action of the peppermint oil is effective as a modulator of gastrointestinal motility and sensation. Chlorophyll may improve bowel activity by stimulation of secretion and motility. This is the first description of this unique mixture of these natural products for the treatment of gastrointestinal conditions.
Owner:EHRENPREIS BEN Z +1
Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
InactiveUS20040229920A1Improve breathabilityHigh viscosityBiocideOrganic chemistryActive agentCerebrovascular disorder
The present invention describes novel nitrosated and / or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and / or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.
Owner:GARVEY DAVID S +1
Veterinary drug for preventing livestock bowel diseases, preparation method of drug, and feed
ActiveCN103006792APrevention and treatment of infectious gastroenteritisPrevention and treatment of piglet yellow and white scourAntibacterial agentsPowder deliveryDiseaseSwine Transmissible Gastroenteritis
The invention discloses a veterinary drug for preventing livestock bowel diseases, a preparation method of the drug, and feed. The veterinary drug contains active ingredients which are prepared from purslane, humifuse euphorbia herb, plantain herb, acalypha australis and liquorice. The veterinary drug provided by the invention has the effects of clearing away heat and toxic materials, eliminating dampness to stop dysentery and astringing to stop bleeding, can be effectively used for preventing the livestock bowel diseases such as swine transmissible gastroenteritis, piglet diarrhea, swine dysentery, chicken salmonellosis, chicken colibacillosis and chicken stphyoococcl disease, and has the advantages of an extensive material source, safety, environment-friendliness, a simple preparation process, low production cost and the like.
Owner:BEIJING DABEINONG ANIMAL HEALTH TECH +1
Chinese medicinal formulation for treating gastrointestinal disease
ActiveCN1970010AInhibition of peristalsisMediation needsHeavy metal active ingredientsDigestive systemDiseaseDisease irritable bowel
The invention relates to a Chinese medicinal composition for treating gastrointestinal tract diseases, which is prepared from the following raw materials (by weight ratio): banksia rose, linaloe, bitter orange, magnolia bark each 2-20 parts, Chinese date 10-60 parts, musk 0.1-0.8 part, defatted powder of croton seed 1-10 parts, sandalwood 1-10 parts, rheum officinale 1-10 parts, rhizome of Sichuan lovage 1-10 parts and cinnabar 1-10 parts.
Owner:津药达仁堂集团股份有限公司乐仁堂制药厂
Goose fermented feed and producing method thereof
InactiveCN102613429ARich sourcesSave food resourcesAnimal feeding stuffBiotechnologyDisease irritable bowel
The invention discloses a goose fermented feed and a producing method thereof. The producing method comprises the steps of: synthesizing corn, soy bean meal, wheat bran, wheat middling, rapeseed meal, pomace, trace elements, vitamins, table salt and beneficial microbial flora; removing impurities according to a rational proportion; grinding the materials into 80-100 meshes rough powders and mixing the powders; mixing mechanically and uniformly and cooling to pelletize; and sealing by plastic bag film, and packaging for warehousing, selling or standby application. Odor in the goose tongue can be changed and environment can be purified by using the goose fermented feed. Meanwhile, the goose fermented feed, disclosed by the invention, has the advantages of saving cost, being low in price, changing the waste into wealth to bring about obvious economic benefit as the raw materials of the goose fermented feed is extremely easy to purchase, being natural, green, ecological and environment-friendly, and having obvious function on preventing goose bowel diseases.
Owner:李雷
Management of gastro-intestinal disorders
ActiveUS20050020931A1Easily toleratedQuick testCompounds screening/testingWithdrawing sample devicesDiseaseDisease irritable bowel
Methods of determining gastro-intestinal conditions by performing a succession of breath tests or others tests, particularly for determining the gastric emptying or gastric accomodation condition of a subject. Methods of performing successive gastric emptying tests with different test meals are also presented, enabling the gastric accommodation to be determined. The effects of different test means on the results is presented. Novel substrates for use in such tests are suggested, including the use of micro-encapsulation. Breath tests for the detection of bacterial overgrowth, lactose intolerance and combinations thereof are presented.
Owner:MERIDIAN BIOSCIENCE ISRAEL LTD
Management of gastro-intestinal disorders
InactiveUS7338444B2Easily toleratedQuick testCompounds screening/testingPerson identificationDiseaseDisease irritable bowel
Owner:EXALENZ BIOSCIENCE LTD
Novel Compounds For The Treatment Of GI Disorders 682
InactiveUS20080262064A1Good curative effectBiocideOrganic active ingredientsAgonistFunctional gastrointestinal disorder
The present invention relates to novel imidazole compounds having a positive allosteric GABAB receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
Owner:ASTRAZENECA AB
Substituted Piperazines as CB1 Antagonists
InactiveUS20090105208A1Lower Level RequirementsBiocideOrganic active ingredientsDiseaseGastrointestinal disorder
Compounds of Formula (I):or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
Owner:SCHERING CORP
Methods for treating GI tract disorders
ActiveUS9132134B2Improving gastric emptyingAntibacterial agentsNervous disorderDiseaseDisease irritable bowel
Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and / or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.
Owner:NEUROGASTRX
Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins
InactiveUS20080213395A1Reduce acidityPromote effectiveHeavy metal active ingredientsBiocideDiseaseDisease irritable bowel
A method for the treatment and / or prophylaxis of disorders of the gastrointestinal system, other disorders selected from post exercise recovery, heat stress, vasovagal states, sleep disorders and fluid loss, and for the maintenance of blood sugar level homeostasis, comprising orally administering to said patient an admixture of vitamins and minerals formulated to have a pH greater than or equal to 5.0 in aqueous solution.
Owner:ADVENTURES PLUS
Novel multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
InactiveUS20050201998A1Effective treatmentReduce usageNervous disorderPeptide/protein ingredientsDisease irritable bowelRegimen
The present invention provides compositions and methods for preventing and treating gastrointestinal disorders by administering to a subject an effective amount of secretin either alone or in combination with an effective amount of oxytocin. The invention also provides compositions and methods for preventing and treating central nervous system disorders by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. The invention further provides compositions and methods for treating and preventing a variety of autoimmune diseases by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. Additionally, the invention provides compositions and methods for preventing and treating pain by administering to a subject using a combination of an effective amount of secretin and an effective amount of oxytocin. The invention also provides kits for use in treating and / or preventing gastrointestinal disorders, central nervous system disorders, autoimmune diseases and pain comprising a combination of secretin and oxytocin.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Compositions and methods for treatment of irritable bowel syndrome with 5-aminosalicylate
InactiveUS20130316000A1Decrease incidenceLow rate and extent of systemic absorptionBiocideOrganic active ingredients5-aminosalicylateGastrointestinal disorder
Embodiments are directed to compositions and related methods for treating gastrointestinal disorders with a granulated mesalamine formulation. In some embodiments, the gastrointestinal disorder being treated is irritable bowel syndrome (IBS). In some embodiments, the gastrointestinal disorder being treated is diarrhea-predominant IBS (d-IBS).
Owner:DR FALK PHARMA GMBH
Novel medicinal application of carboxyl aminotriazole and acceptable salts of the carboxyl aminotriazole
ActiveCN101618036AOrganic active ingredientsNervous disorderAmyotrophic lateral sclerosisPharmacology
The invention discloses application of carboxyl aminotriazole or pharmaceutically acceptable salts of the carboxyl aminotriazole in the preparation of medicaments for preventing and / or treating neurodegenerative diseases, amyotrophic lateral sclerosis and inflammatory bowel diseases and also relates to the medicament packages or kits comprising the medicaments.
Owner:GUANGDONG YINZHU PHARMACEUTICAL TECHNOLOGY CO LTD
Substituted piperazines as CB1 antagonists
InactiveUS20130072468A1Lower Level RequirementsBiocideOrganic active ingredientsDisease irritable bowelPharmaceutical medicine
Compounds of Formula (I):or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
Owner:GILBERT ERIC J +4
Novel Cannabinergic Compounds and Uses Thereof
Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.
Owner:NORTHEASTERN UNIV
Treatment of irritable bowel syndrome and related bowel diseases
InactiveUS7704985B2Minimal and systemic side effectOrganic active ingredientsDigestive systemDisease irritable bowelSide effect
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Substituted piperazines as CB1 antagonists
InactiveUS8623873B2Lower Level RequirementsOrganic active ingredientsBiocideDisease irritable bowelPharmaceutical medicine
Compounds of Formula (I):or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
Owner:SCHERING CORP
Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
ActiveUS20200405777A1Increase productionIncrease the number ofBacteriaMetabolism disorderDisease irritable bowelDisease
The present invention relates generally to medicine. More specifically the invention relates to the use of synergistic probiotic bacteria as intervention for health. In particular, the present invention provides a strain of Faecalibacterium prausnitzii and a bacterial strain which has one or more of the characteristics of: (i) being acetate producing, (ii) being lactate consuming and (iii) having the ability to be an electron acceptor, for use in the treatment or prevention of a disease associated with reduced butyrate levels or a disease associated with reduced or low numbers of Faecalibacterium prausnitzii bacteria.
Owner:METABOGEN
System and Method for Carbon Particle Therapy for Treatment of Cardiac Arrhythmias and Other Diseases
PendingUS20200179722A1Eliminate tachycardiaSaferImage enhancementReconstruction from projectionDisease irritable bowelDisease
Particle or hadron therapy is used on abnormal tissue using carbon atoms, protons, or helium atoms run through a linear accelerator and then directed at the target in the body. This can be used to treat, for example, atrial fibrillation, ventricular tachycardia, hypertension, seizures, gastrointestinal maladies, etc. Contouring and gating may be used to account for cardiac and respiratory motion, helping reduce collateral damage.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Lactobacillus gasseri KBL697 strain and use thereof
ActiveUS11285183B2Good effectImprove Gut HealthCosmetic preparationsAntimycoticsDisease irritable bowelAnti fungal
Owner:KO BIOLABS INC
Method of treating protozoal gastrointestinal disorders in immunocompromised patients
ActiveUS10478493B2Reduce in quantityRelieve symptomsVitamin food ingredientsMilk immunoglobulinsDisease irritable bowelProtozoa
Owner:STOLLE MILK BIOLOGICS
Polyhydroxystilbenes and stibene oxides as antisoriatic agents and protein kinase inhibitors
InactiveCN1319959COrganic chemistryHydroxy compound active ingredientsDisease irritable bowelPTK Inhibitors
Owner:BEIJING WEN FENG TIANJI PHARMA CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com